Zydus Lifesciences Limited Share Price Today
Techno Funda Ratings
Key Metrics
Current Price
₹1143.7Market Cap
₹ 1,14,124 Cr.Stock P/E
21.0ROE
21.2 %RSI
63.98Trend
BullishShare Price Chart
Technical Commentary
Buy or Sell Analysis
Company Overview
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
Zydus Lifesciences Ltd share price remains one of the actively tracked stocks on NSE among traders and long term investors.
The latest Zydus Lifesciences Ltd share price NSE movement reflects ongoing investor interest driven by company fundamentals, sector performance and broader market sentiment.
From a technical analysis perspective, the Zydus Lifesciences Ltd share price chart currently indicates a Bullish trend based on moving averages and RSI momentum analysis.
Technical Analysis
| Indicator | Value |
|---|---|
| Current Price | 1143.7 |
| RSI (14) | 63.98 |
| 50 DMA | 1084.29 |
| 200 DMA | 964.97 |
| Trend | Bullish |
| A/D Rating | B |
| RS Rating | 82 |
| EPS Rating | 48 |
| TI65 | 1.1 |
| TI65 Trend | Bullish |
Pivot Points Analysis
Daily pivot points for Zydus Lifesciences Limited calculated using previous trading session data. These levels help traders identify intraday support, resistance and breakout zones using Classic Pivot Point methodology.
Classic Pivot Points
| Level | Value |
|---|---|
| R3 | ₹1177.24 |
| R2 | ₹1166.97 |
| R1 | ₹1155.34 |
| PP | ₹1145.07 |
| S1 | ₹1133.44 |
| S2 | ₹1123.17 |
| S3 | ₹1111.54 |
Financial Ratios
| Metric | Value |
|---|---|
| Market Cap | ₹ 1,14,124 Cr. |
| Current Price | ₹ 1,144 |
| High / Low | ₹ 1,182 / 836 |
| Stock P/E | 21.0 |
| Book Value | ₹ 269 |
| Dividend Yield | 0.09 % |
| ROCE | 21.1 % |
| ROE | 21.2 % |
| Face Value | ₹ 1.00 |
Quarterly Results
| Quarter | Sales | Profit | OPM |
|---|---|---|---|
| Mar 2023 | 5,011 | 358 | 25% |
| Jun 2023 | 5,140 | 1,134 | 29% |
| Sep 2023 | 4,369 | 803 | 26% |
| Dec 2023 | 4,505 | 790 | 24% |
| Mar 2024 | 5,534 | 1,246 | 29% |
| Jun 2024 | 6,208 | 1,482 | 34% |
| Sep 2024 | 5,237 | 920 | 28% |
| Dec 2024 | 5,269 | 1,026 | 26% |
| Mar 2025 | 6,528 | 1,244 | 33% |
| Jun 2025 | 6,574 | 1,521 | 32% |
| Sep 2025 | 6,123 | 1,239 | 33% |
| Dec 2025 | 6,864 | 1,023 | 26% |
| Mar 2026 | 7,587 | 1,341 | 34% |
Shareholding Pattern
| Holder | Holding |
|---|---|
| Promoters | 74.79% |
| FIIs | 9.88% |
| DIIs | 7.11% |
| Government | 0.15% |
| Public | 8.07% |
| No. of Shareholders | 82,783 |
Pros and Cons
Pros
- Healthy return on equity of 21.2% indicating strong capital allocation efficiency.
- Strong technical momentum with price holding comfortably above the 50 DMA (1084.29).
- Outperforming over 70% of the entire market universe over the past 12 months.
Cons
Related NSE Stocks
Canara HSBC Life Insurance Company Limited
View Share Price Analysis →Titan Company Limited
View Share Price Analysis →Dr. Reddy's Laboratories Limited
View Share Price Analysis →Balkrishna Industries Limited
View Share Price Analysis →Trent Limited
View Share Price Analysis →Poly Medicure Limited
View Share Price Analysis →Jindal Saw Limited
View Share Price Analysis →Deepak Nitrite Limited
View Share Price Analysis →Saregama India Limited
View Share Price Analysis →Vardhman Textiles Limited
View Share Price Analysis →The Phoenix Mills Limited
View Share Price Analysis →Leela Palaces Hotels & Resorts Limited
View Share Price Analysis →Frequently Asked Questions
What is the current technical trend and RSI for Zydus Lifesciences Ltd share?
Based on the latest closing data, the technical momentum for Zydus Lifesciences Ltd is currently evaluated as Bullish. The stock is exhibiting an RSI (14) of 63.98, indicating it is trading in a neutral balanced zone. Key tracking supports are currently located near the daily pivots, with price relative to the 50 DMA (1084.29) defining immediate multi-day trend patterns.
What are the key resistance and support pivot points for Zydus Lifesciences Ltd?
According to Classic Pivot Point methodologies, the core trading floor for Zydus Lifesciences Ltd today centers at a Pivot Point (PP) of ₹1145.07. Upside resistance challenges are calculated at R1: ₹1155.34, R2: ₹1166.97, and R3: ₹1177.24. Conversely, if selling pressure intensifies, immediate floor support targets are positioned at S1: ₹1133.44, S2: ₹1123.17, and S3: ₹1111.54.
How does the fundamental ROE and P/E ratio look for Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd is currently trading with a valuation metrics context of a Stock P/E of 21.0, against a core structural efficiency Return on Equity (ROE) standing at 21.2 %. This fundamental operational efficiency baseline is coupled with an EPS Rating of 48, allowing investors to track how corporate profitability trends align with current price discovery cycles on the National Stock Exchange (NSE).
Should I buy or sell Zydus Lifesciences Ltd shares based on corporate rankings?
Our dynamic trade matrix suggests a status of: Speculative Momentum Phase (Neutral / Hold). Zydus Lifesciences Ltd is trading a... For long-term portfolios, decision-making should match the stock's market performance profile, which currently displays an institutional Accumulation/Distribution (A/D) grade of B, a Relative Strength (RS) ranking of 83, and long-term trend backing from the TI65 indicator (Bullish pattern).